HRTX
Heron Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →
Heron Therapeutics, Inc. (HRTX) closed at $0.78 as of 2026-03-20, trading 63.4% below its 200-week moving average of $2.13. This places HRTX in the extreme value zone. The stock is currently moving closer to the line, down from -58.9% last week. With a 14-week RSI of 24, HRTX is in oversold territory.
Trading volume is running at 1.4x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.50 ratio) is neutral — neither side is clearly dominating.
Over the past 1964 weeks of data, HRTX has crossed below its 200-week moving average 28 times. On average, these episodes lasted 51 weeks. Historically, investors who bought HRTX at the start of these episodes saw an average one-year return of +28.2%.
With a market cap of $147 million, HRTX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at 11.0x book value.
Share count has increased 58.0% over three years, indicating dilution.
Over the past 33.2 years, a hypothetical investment of $100 in HRTX would have grown to $0, compared to $2683 for the S&P 500. HRTX has returned -18.5% annualized vs 10.4% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 2 open-market purchases totaling $6,230,657. Notably, these purchases occurred while HRTX is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: HRTX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After HRTX Crosses Below the Line?
Across 25 historical episodes, buying HRTX when it crossed below its 200-week moving average produced an average return of +28.6% after 12 months (median -15.0%), compared to +13.5% for the S&P 500 over the same periods. 44% of those episodes were profitable after one year. After 24 months, the average return was +4.6% vs +31.2% for the index.
Each line shows $100 invested at the moment HRTX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
HRTX has crossed below its 200-week MA 28 times with an average 1-year return of +28.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Sep 1988 | Jan 1989 | 15 | 27.3% | N/A | -99.9% |
| Mar 1989 | Mar 1989 | 1 | 0.0% | -34.5% | -99.9% |
| Jun 1989 | Sep 1991 | 117 | 64.6% | -1.8% | -99.9% |
| Mar 1993 | May 1993 | 7 | 19.5% | +9.8% | -99.8% |
| May 1993 | Jun 1993 | 2 | 1.0% | -20.4% | -99.9% |
| Jun 1993 | Mar 1994 | 37 | 26.6% | -19.2% | -99.9% |
| Mar 1994 | Sep 1995 | 77 | 43.8% | -33.7% | -99.8% |
| Oct 1995 | Jan 1996 | 13 | 23.6% | +23.8% | -99.9% |
| Dec 1997 | Feb 1998 | 8 | 7.6% | -14.2% | -99.9% |
| Jun 1998 | Oct 2003 | 278 | 76.3% | -10.7% | -99.8% |
| Nov 2003 | Dec 2003 | 3 | 7.9% | -44.1% | -99.6% |
| Dec 2003 | Dec 2003 | 1 | 0.8% | -28.6% | -99.6% |
| Aug 2004 | Jan 2005 | 24 | 43.0% | +31.8% | -99.3% |
| Feb 2005 | Jan 2006 | 48 | 26.5% | +5.5% | -99.5% |
| May 2006 | Jun 2012 | 319 | 89.0% | -45.3% | -99.5% |
| Jul 2012 | Jul 2012 | 1 | 0.6% | -27.4% | -93.7% |
| Oct 2012 | Jan 2013 | 14 | 17.4% | -40.7% | -93.4% |
| Mar 2013 | Jan 2014 | 45 | 47.8% | +31.2% | -92.9% |
| Jul 2014 | Aug 2014 | 5 | 7.2% | +301.0% | -91.3% |
| Sep 2014 | Dec 2014 | 13 | 21.9% | +319.2% | -91.4% |
| Jan 2015 | Feb 2015 | 4 | 12.2% | +185.7% | -90.2% |
| Oct 2016 | Nov 2016 | 2 | 2.1% | -0.3% | -94.9% |
| Dec 2016 | Jul 2017 | 32 | 19.9% | +7.0% | -94.8% |
| Jul 2017 | Nov 2017 | 16 | 9.2% | +126.6% | -95.2% |
| Dec 2017 | Dec 2017 | 2 | 7.5% | +66.5% | -95.1% |
| Apr 2019 | Oct 2019 | 26 | 24.8% | -19.4% | -95.4% |
| Jan 2020 | Jan 2020 | 1 | 1.2% | -6.7% | -96.3% |
| Jan 2020 | Ongoing | 321+ | 93.8% | Ongoing | -96.3% |
| Average | 51 | — | +28.2% | — |
Frequently Asked Questions
Is HRTX below its 200-week moving average?
Yes. As of 2026-03-20, Heron Therapeutics, Inc. (HRTX) is trading 63.4% below its 200-week moving average of $2.13. The current price is $0.78.
What is HRTX's 200-week moving average price?
Heron Therapeutics, Inc.'s 200-week moving average is $2.13 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when HRTX drops below its 200-week moving average?
HRTX has crossed below its 200-week moving average 28 times in our data. On average, buying at that moment produced a one-year return of +28.2%. These dips have historically been decent entry points. These episodes lasted 51 weeks on average.
Is HRTX a good value right now?
Here's what our data says about HRTX as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 24 (oversold). Free cash flow is currently negative. Price-to-book is 11.0x. This is not a buy or sell recommendation — always do your own research.
How does HRTX compare to the S&P 500?
Over the past 33.2 years, $100 invested in HRTX would have grown to $0, compared to $2683 for the S&P 500. That's -18.5% annualized vs 10.4% for the index. HRTX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20